Kenvue Inc.
As of Oct 22, 2026, Kenvue is in Stage 3, the topping phase, now in week 5 (since Sep 22, 2026). It closed at $19.88, at its 52-week high and above its 200-day average, which is rising.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is KVUE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KVUE among Household & Personal Products6th of 30 by relative strength
All 30 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | SKIN | Stage 2 · wk 2 | 99 | +1538.8% |
| 2 | ACU | Stage 2 · wk 17 | 92 | +2.5% |
| 3 | HELE | Stage 3 · wk 3 | 86 | −1.9% |
| 4 | EPC | Stage 2 · wk 17 | 86 | +6.7% |
| 5 | SPB | Stage 3 · wk 3 | 86 | −6.3% |
| 6 | KVUE | Stage 3 · wk 5 | 82 | +12.5% |
| 7 | HNST | Stage 2 · wk 22 | 80 | −6.2% |
| 8 | CL | Stage 3 · wk 6 | 74 | +14.0% |
Kenvue: quick answers
What stage is Kenvue in?
As of Oct 22, 2026, Kenvue (KVUE) is in Stage 3, the topping phase. It entered Stage 3 on Sep 22, 2026 and is in week 5. What the four stages mean
Is Kenvue in an uptrend?
Its uptrend has stalled. Kenvue is in Stage 3, the topping phase that follows an advance. It trades 12.5% above its 200-day average, which is rising.
How far is Kenvue from its 52-week high?
Kenvue closed at $19.88 on Oct 22, 2026, at its 52-week high. Its 52-week low is $13.43.
How has Kenvue performed over the past year?
As of Oct 22, 2026, Kenvue is up 41.2% over the past year and up 20.2% so far in 2026.
Which sector and industry is Kenvue in?
Kenvue is in the Household & Personal Products industry, part of the Consumer Staples sector.
About this companyConsumer Staples· Household & Personal Products
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.